6th Oct 2025 11:50
Verici Dx PLC - Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants - Reports "positive progress" in its plans to drive sales growth for Tutivia, its flagship kidney transplant diagnostic test. Says commercial scale-up of Tutivia test adoption has progressed in the third quarter with ordering clinicians rising 19%. Verici has also onboarded nine new transplant centres, bringing the total to 30 centres which represent 16% of annual transplants in the US. Says orders in the third quarter were consistent with the previous two, and expects volume growth in the fourth. Company also says it has expanded its commercial team with three new senior sales hires; a new director of clinical partnerships joins in mid-October; and Aubrey Powell joins the board as a non-executive director with Mount Sinai representative Erik Lium stepping down. The firm continues "to target meeting expectations" for its full-year 2025 results.
Current stock price: 0.78 pence, up 21% in London on Monday morning
12-month change: down 88%
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Verici Dx